Skip to main content

Sanfilippo Syndrome Type A

0
Pipeline Programs
3
Companies
13
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Human BioSciences
Human BioSciencesWV - Martinsburg
1 program
Neurobehavioral Phenotypes in MPS IIIN/A1 trial
Active Trials
NCT01873911Completed30Est. Aug 2014
Takeda
TakedaTOKYO, Japan
1 program
assessmentN/A5 trials
Active Trials
NCT06252493Recruiting25Est. Dec 2029
NCT04938440Completed536Est. Feb 2023
NCT03681015Completed132Est. Mar 2022
+2 more trials
GC Biopharma
GC BiopharmaKorea - Yongin
1 program
GC1130APHASE_11 trial
Active Trials
NCT06567769Recruiting9Est. Jun 2027

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
Takedaassessment
Takedaassessment
Takedaassessment
GC BiopharmaGC1130A
Takedaassessment
Takedaassessment
Takedaassessment
Takedaassessment
Takedaassessment
Human BioSciencesNeurobehavioral Phenotypes in MPS III
Takedaassessment
Takedaassessment
Takedaassessment

Clinical Trials (13)

Total enrollment: 1,602 patients across 13 trials

An Assessment of Chronic Synovial-Based Inflammation and Its Role With Serum Urate Levels.

Start: May 2010Est. completion: Dec 201474 patients
Phase 4Completed

Symptom Assessment in Adult Patients With Erosive GERD (Gastroesophageal Reflux Disease) or enGERD (Endoscopic-negative GERD) After Treatment With Pantoprazole (BY1023/M3-343)

Start: Aug 2006Est. completion: Apr 2007628 patients
Phase 3Completed

Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Start: Jan 2019Est. completion: Oct 202740 patients
Phase 2Active Not Recruiting

Phase 1 Study of GC1130A in Patients With Sanfilippo Syndrome Type A (MPS IIIA)

Start: Nov 2024Est. completion: Jun 20279 patients
Phase 1Recruiting

Taste Assessment Study of SHP429 in Healthy Adult Subjects

Start: Jun 2014Est. completion: Jun 201418 patients
Phase 1Completed

Value of PET/MR Enterography in the Assessment of Crohn's Disease Using a Collagen-binding Radiotracer.

Start: Dec 2023Est. completion: Dec 202925 patients
N/ARecruiting

Assessment of Updated Educational Materials for Instanyl®

Start: Feb 2022Est. completion: Feb 2023536 patients
N/ACompleted

Wearable Assessments in the Clinic and Home in PD

Start: Apr 2019Est. completion: Mar 2022132 patients
N/ACompleted

Assessment of Immune Activation and Tolerance in Celiac Disease During Gluten Challenge

Start: Apr 2018Est. completion: May 201916 patients
N/ACompleted
NCT01873911Human BioSciencesNeurobehavioral Phenotypes in MPS III

Neurobehavioral Phenotypes in MPS III

Start: Dec 2010Est. completion: Aug 201430 patients
N/ACompleted

Sophisticated Assessment of Disease Burden in Patients With Fabry Disease

Start: Oct 2010Est. completion: Sep 201336 patients
N/ACompleted

A Study of Patients With Sanfilippo Syndrome Type A (MPS IIIA)

Start: Feb 2010Est. completion: Jul 201325 patients
N/ACompleted

Screening Study to Identify Pediatric Patients With Hunter Syndrome Who Demonstrate Evidence of Central Nervous System (CNS) Involvement and Who Are Currently Receiving Treatment With Elaprase®

Start: Jul 2009Est. completion: Jul 201133 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 actively recruiting trials targeting 1,602 patients
3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.